MX378457B - Anticuerpos siglec de reacciòn cruzada. - Google Patents

Anticuerpos siglec de reacciòn cruzada.

Info

Publication number
MX378457B
MX378457B MX2017002856A MX2017002856A MX378457B MX 378457 B MX378457 B MX 378457B MX 2017002856 A MX2017002856 A MX 2017002856A MX 2017002856 A MX2017002856 A MX 2017002856A MX 378457 B MX378457 B MX 378457B
Authority
MX
Mexico
Prior art keywords
cross reactive
siglec antibodies
reactive siglec
agents
antibodies
Prior art date
Application number
MX2017002856A
Other languages
English (en)
Other versions
MX2017002856A (es
Inventor
Benjamin Rossi
Nicolaï Wagtmann
Stéphanie Cornen
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54072835&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX378457(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innate Pharma filed Critical Innate Pharma
Publication of MX2017002856A publication Critical patent/MX2017002856A/es
Publication of MX378457B publication Critical patent/MX378457B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un anticuerpo monoclonal iaslado caracterizado porque enlaza específicamente a un polipéptido Siglec-7 humano y a un polipéptido Siglec-9 humano, en donde el anticuerpo provoca un incremento en la expresión de CD137 en células NK que expresan Siglec cuando las células NK se ponen en contacto con una célula humana objetivo que porta un ligando del Siglec sobre la superficie de la célula objetivo.
MX2017002856A 2014-09-10 2015-09-09 Anticuerpos siglec de reacciòn cruzada. MX378457B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462048292P 2014-09-10 2014-09-10
PCT/EP2015/070550 WO2016038064A1 (en) 2014-09-10 2015-09-09 Cross reactive siglec antibodies

Publications (2)

Publication Number Publication Date
MX2017002856A MX2017002856A (es) 2017-05-30
MX378457B true MX378457B (es) 2025-03-11

Family

ID=54072835

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002856A MX378457B (es) 2014-09-10 2015-09-09 Anticuerpos siglec de reacciòn cruzada.

Country Status (8)

Country Link
US (1) US20170306014A1 (es)
EP (1) EP3191517B1 (es)
JP (2) JP2017532025A (es)
AU (1) AU2015314316B2 (es)
CA (1) CA2957351A1 (es)
DK (1) DK3191517T3 (es)
MX (1) MX378457B (es)
WO (1) WO2016038064A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2957351A1 (en) 2014-09-10 2016-03-17 Innate Pharma Cross reactive siglec antibodies
CN107849148B (zh) 2015-05-21 2023-09-19 哈普恩治疗公司 三特异性结合蛋白质及使用方法
AU2016299166B2 (en) 2015-07-24 2022-03-31 Innate Pharma Methods for detecting tissue infiltrating NK cells
WO2017040301A1 (en) * 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
KR20180084817A (ko) * 2015-10-29 2018-07-25 알렉터 엘엘씨 항-siglec-9 항체 및 이의 이용 방법
AU2016354924A1 (en) 2015-11-17 2018-06-21 Innate Pharma Siglec-10 antibodies
CA3011092A1 (en) * 2016-01-12 2017-07-20 Palleon Pharmaceuticals Inc. Use of siglec-7 or siglec-9 antibodies for the treatment of cancer
US11078274B2 (en) * 2016-03-08 2021-08-03 Innate Pharma Siglec neutralizing antibodies
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2018006034A1 (en) * 2016-07-01 2018-01-04 The Board Of Trustees Of The Leland Stanford Junior University Conjugates for targeted cell surface editing
GB201611535D0 (en) * 2016-07-01 2016-08-17 King S College London Methods and compositions for treating cancer with siglec-9 activity modulators
EP3478315A4 (en) * 2016-07-01 2020-03-25 The Board of Trustees of the Leland Stanford Junior University METHODS AND COMPOSITIONS FOR INHIBITING THE INHIBITOR IMMUNE RECEPTOR
EP3494142A4 (en) * 2016-08-05 2020-04-01 Allakos, Inc. ANTI-SIGLEC-7 ANTIBODIES FOR THE TREATMENT OF CANCER
CN106831989A (zh) * 2017-01-04 2017-06-13 中国人民解放军南京军区军事医学研究所 人源抗唾液酸结合免疫球蛋白样凝集素‑7的抗体IgG及其应用
CN113896792B (zh) 2017-05-12 2025-08-22 哈普恩治疗公司 间皮素结合蛋白质
AU2018298673A1 (en) * 2017-07-10 2019-12-19 Innate Pharma Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer
CA3066514A1 (en) * 2017-07-10 2019-01-17 Innate Pharma Siglec-9-neutralizing antibodies
CN111295394B (zh) * 2017-08-11 2024-06-11 豪夫迈·罗氏有限公司 抗cd8抗体及其用途
KR102425983B1 (ko) 2017-10-13 2022-07-29 하푼 테라퓨틱스, 인크. 삼중특이적 단백질 및 사용 방법
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
WO2019136167A1 (en) 2018-01-03 2019-07-11 Palleon Pharmaceuticals Inc. Recombinant human sialidases, sialidase fusion proteins, and methods of using the same
CA3087968A1 (en) * 2018-01-11 2019-07-18 Allakos, Inc. Anti-siglec-7 antibodies having reduced effector function
CA3101988A1 (en) * 2018-06-07 2019-12-12 Palleon Pharmaceuticals Inc. Multimeric proteins for detecting a carbohydrate and/or treating a siglec-mediated disorder
JP7382970B2 (ja) * 2018-06-08 2023-11-17 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
IL281683B2 (en) 2018-09-25 2023-04-01 Harpoon Therapeutics Inc dll3 binding proteins and methods of use
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CN114667298A (zh) 2019-11-04 2022-06-24 艾利妥 Siglec-9 ecd融合分子及其使用方法
WO2022006113A1 (en) * 2020-06-30 2022-01-06 The Board Of Trustees Of The Leland Stanford Junior University Cis-binding siglec agonists and related compositions and methods
CA3182579A1 (en) 2020-07-07 2022-01-13 Ugur Sahin Therapeutic rna for hpv-positive cancer
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
JP2024525758A (ja) 2021-07-13 2024-07-12 ビオンテック・ソシエタス・エウロパエア がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
CN117736270B (zh) * 2023-11-29 2024-08-02 南京市第一医院 靶向蛋白siglec-10抑制炎症的多肽及其在脓毒症中的应用
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002326531A1 (en) * 2001-08-03 2003-02-17 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbb family members and methods of use thereof
JP2006265155A (ja) * 2005-03-23 2006-10-05 Link Genomics Kk 癌の免疫療法
WO2014120642A1 (en) * 2013-01-30 2014-08-07 The General Hospital Corporation Diagnosis and treatment of hepatorenal syndrome
CA2957351A1 (en) 2014-09-10 2016-03-17 Innate Pharma Cross reactive siglec antibodies

Also Published As

Publication number Publication date
US20170306014A1 (en) 2017-10-26
EP3191517A1 (en) 2017-07-19
MX2017002856A (es) 2017-05-30
CA2957351A1 (en) 2016-03-17
EP3191517B1 (en) 2020-11-04
JP2022109920A (ja) 2022-07-28
AU2015314316A1 (en) 2017-03-09
JP2017532025A (ja) 2017-11-02
AU2015314316B2 (en) 2020-12-10
DK3191517T3 (da) 2021-01-25
WO2016038064A1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
MX378457B (es) Anticuerpos siglec de reacciòn cruzada.
PH12016501456A1 (en) Antibody molecules to pd-1 and uses thereof
PH12018501206A1 (en) Antibody molecules to pd-1 and uses thereof
MX2022001043A (es) Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas.
MX2020002694A (es) Moleculas de anticuerpo que se unen a tim-3 y usos de las mismas.
PH12017500692A1 (en) Antibody molecules to pd-l1 and uses thereof
MX2022001105A (es) Anticuerpos anti tigit.
PH12017500803A1 (en) Anti-pd-1 antibodies
EP4378957A3 (en) Combination therapies comprising antibody molecules to pd-1
WO2015185875A9 (fr) Anticorps dirigé contre la galectine 9 et inhibiteur de l'activité suppressive des lymphocytes t régulateurs
IL256691A (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
WO2015116868A3 (en) Molecular profiling of immune modulators
NZ631701A (en) Apoptosis-including agents for the treatment of cancer and immune and autoimmune diseases
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
ZA201706402B (en) C.novyi for the treatment of solid tumors in humans
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
GB201317219D0 (en) Treated waste products, methods of preparing them and using the same
PT2862576T (pt) Microrganismos e composições que os compreendem para utilização no tratamento ou prevenção de mastite
HK1231933A1 (en) Aptamer construct
TH1601001559A (th) สารเชิงซ้อนที่มีโอลิโกนิวคลีโอไทด์ที่มีแอคทิวิตีการเสริมฤทธิ์ทางอิมมูน และการใช้ของมัน
HK1226329A1 (en) Apilimod compositions and methods for using same
GB2546703A (en) Compounds
GB201408854D0 (en) Processing transactions using multiple financial sources
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes